The metabolic syndrome and dyslipidemia in primary and secondary prevention: examining the implications of recent trials

Abstract

The dyslipidemia associated with the metabolic syndrome, particularly involving elevated triglycerides, low HDL-C, and small dense LDL-C, is a key atherogenic component of the metabolic syndrome. The aim of this article is to review the studies that address the substantial residual cardiovascular risk that remains despite the intensification of therapies designed to affect lipoprotein concentrations. The article further elaborates on the confluence of recent studies that focus not only on modifications of lipoprotein subfractions, but also on how these modifications, in the context of the metabolic syndrome, can result in the reduction of cardiovascular risk.

Keywords:

• dyslipidemia
• metabolic syndrome
• residual risk